Artificial Intelligence (AI) has achieved remarkable successes in recent years. It can defeat human champions in games like Go, predict protein structures with high accuracy, and perform complex tasks ...
Abstract: Nowadays, as the demand for accurate object detection (OD) applications is increasing, several attempts have been made to introduce convolutional neural network (CNN)-based super-resolution ...
Abstract: Current adversarial attacks pose a serious threat to the robustness of visual-language models (VLMs), including vision-language pre-trained models (VLPMs) and multimodal large language ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...
Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
If only they were robotic! Instead, chatbots have developed a distinctive — and grating — voice. Credit...Illustration by Giacomo Gambineri Supported by By Sam Kriss In the quiet hum of our digital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback